CAR T-Cell Therapy Response Varies by Extranodal Disease Site in Large B-Cell Lymphoma

Investigators retrospectively analyzed 283 adults treated with commercial CD19 CAR-T therapy, assessing 958 PET-CT scans across four time points: pre-apheresis, pre-lymphodepletion, best response, and relapse.